QIAGEN Acquires Biosystems Business from Biotage

Transaction adds fundamental assay technology for high-resolution sequence detection and quantification of genetic variations

06-Oct-2008 - QIAGEN N.V. announced that it has acquired all assets related to the Biosystems business from Biotage AB, a publicly listed developer, manufacturer and distributor of products for genetic analysis and medicinal chemistry headquartered in Uppsala, Sweden. The transaction is valued at approximately ...

Seegene and Shimadzu Agree to Join Multi-Pathogen Tests and Platform for Combined Analytics Solution

30-Jul-2008 - Seegene, Inc. and Shimadzu Corporation announced a strategic partnership to combine Seegene's Seeplex(R) multi-pathogen tests with Shimadzu's MultiNA (1) analytical platform. Under terms of the deal, Shimadzu and Seegene will collaborate on integrating the Seeplex polymerase chain reaction-based ...

QIAGEN Signs Agreement for the Acquisition of eGene

Strategic Transaction adds Capillary Sample Separation Technology Targeting Molecular Diagnostics and Other Applications

17-Apr-2007 - QIAGEN N.V. announced, that its subsidiary QIAGEN North American Holdings, Inc. has signed a definitive merger agreement with eGene, Inc. pursuant to which eGene would become a fully owned subsidiary of QIAGEN North American Holdings, Inc. eGene is an early-stage company, that has developed and ...

GeneBio and Genedata Integrate Computational Platforms to Support Large-Scale Proteomics Projects

28-Oct-2005 - Geneva Bioinformatics (GeneBio) SA and Genedata AG announced a collaboration that will offer life science researchers a precise, high-throughput solution for analyzing proteomics data. The two companies will integrate the Genedata Expressionist® solution with the Melanie/ImageMaster(TM) 2D ...

Applied Biosystems to Invest in VisiGen Biotechnologies

Next Generation Sequencing Technology May Hold Promise of the $1,000 Genome

28-Oct-2005 - Applied Biosystems Group, an Applera Corporation business, and VisiGen Biotechnologies, Inc., announced that Applied Biosystems has signed a definitive agreement to make an equity investment in privately held VisiGen, a next-generation sequencing technology company, and to enter into a scientific ...

Emerging Market for Protein Microarrays Shows Strong Growth

30-Sep-2005 - As protein arrays have become increasingly consistent and reliable, more scientists have begun to incorporate them into their experiments. A recent study of proteomics researchers reveals that while 34% of respondents currently use protein microarrays, 48% plan to use them in the future. Among ...

Agilent Technologies, Human Metabolome Technologies collaborate on metabolomics solution to speed disease and drug research

22-Jun-2005 - Agilent Technologies Inc. and Human Metabolome Technologies, a Japanese bioventure, announced they have signed an agreement to collaborate on an integrated set of metabolome analysis tools designed to help researchers discover potential therapeutics. Under the agreement, the two companies will ...

Applied Biosystems/MDS Sciex is the Top Supplier in the Mass Spectrometer Market

17-May-2005 - According to a recent survey of life scientists using mass spectrometry (MS) in their research, Applied Biosytems/MDS Sciex is the leading mass spectrometer brand in all regions and market segments, followed by Agilent Technologies and Thermo Finnigan. Customers of these three leading brands are ...

Genomics and Proteomics to Increase the Efficiency of Drug Discovery and Development

07-Apr-2005 - While the United States is still the world leader, Europe is having a good deal of success in the field of advanced genomics and proteomics research. Significant government funding together with the presence of large pharmaceutical companies has made Europe a major competitor in the efforts to ...

Microchip Biotechnologies Awarded $6.1M Grant to Build Next-Generation DNA Sequencer

12-Nov-2004 - Microchip Biotechnologies Inc. (MBI) has been awarded a $6.1 million grant from the National Human Genome Research Institute (NHGRI) to develop an innovative nanofluidic technological platform that promises to dramatically reduce the cost of DNA sequencing. The grant was the largest in a series ...